Hints and tips:
...Geoff Meacham, analyst at Bank of America, said a rejection “is not necessarily going to put a death nail in the coffin of the amyloid hypothesis” because Biogen’s controversial trials are difficult to compare...
...However, Mr Meacham says some investors would like to see the company diversify by acquiring a smaller biotech group with a different focus....
...“Companies will need to fundamentally revisit their way of working and transform themselves,” says Matthew Meacham, Bain’s global head of consumer products....
...However, Geoff Meacham of Barclays said: “We continue to maintain that this case is far from over and will probably take a few years to play out in appeals.”...
...Meacham vividly captures the tribulations of that period and offers a remarkable tale of how quickly fortunes can change even for the most accomplished statesmen....
...Mr Meacham said: “We view it more as election season rhetoric than a push toward near-term structural changes.’’...
...biotech industry over the early part of this decade, highlighted by cures in hepatitis C and transformative advances in prostate cancer, multiple sclerosis and numerous orphan diseases,” said Geoffrey Meacham...
...conviction level is high on the industry given what we believe will be another strong year for biotech innovation and a differentiated earnings growth profile versus the broader markets,” says Geoffrey Meacham...
...Jon Meacham, editor of Newsweek, is attempting to put together a bid for the troubled news magazine after the Washington Post Company put it up for sale, saying it could not see a way to return it to long-term...
...“I’m going to explore every possibility to see that Newsweek’s voice continues to play a role in the global conversation,” Mr Meacham told the FT....
...Meacham ends his book by reminding us of the esteem in which Theodore and Franklin Roosevelt held Jackson, a sentiment shared by Harry Truman....
International Edition